Hyunseok Kang
University of California, San Francisco · 236 works · 8,248 citations · h-index 37
Top works
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
- Emerging biomarkers in head and neck cancer in the era of genomics
- Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria)—Interreader Reliability, Accuracy, and Survival Outcomes
- Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method
- Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
- Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy
- Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study
- Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
- Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion
- Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board
- Evaluation of proposed staging systems for human papillomavirus‐related oropharyngeal squamous cell carcinoma
- Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma